Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Oral Doses of BI 706321 in Healthy Volunteers
NCT04241458Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bi 706321 in Crohn's disease (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events up to 27 days. Started Jan 2020; status: completed.
02
Drugs
bi 706321
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04241458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241458.